ZCCN INFO
832171
WUXI JINGHAI
836547
KLT
831689
4
TIRAIN
430564
5
ZHONGKE MEILING
835892
CN Stock MarketDetailed Quotes
000919 Jinling Pharmaceutical
- 6.84
- +0.10+1.48%
Market Closed Mar 14 15:00 CST
4.27BMarket Cap57.97P/E (TTM)
6.84High6.72Low121.18KlotVolume6.73Open6.74Pre Close82.29MTurnover2.05%Turnover Ratio42.75P/E (Static)623.71MShares7.8552wk High1.13P/B4.04BFloat Cap5.5552wk Low7.41Limit Up590.36MShs Float29.05Historical High6.07Limit Down1.78%Amplitude0.09Historical Low0.10Dividend TTM6.79Avg Price48.83KlotAsk1.46%Div YieldTTM100Lot Size71.90KlotBid
Jinling Pharmaceutical News
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Jinling Pharmaceutical (000919.SZ): has noted the impact of AI applications on the pharmaceutical Industry and will study relevant possible applications according to needs and industry development conditions.
Gelonghui, February 24th丨Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform that the company has paid attention to the impact of AI applications on the pharmaceutical Industry and will study relevant possible applications as needed and according to the development status of the Industry.
Jinling Pharmaceutical (000919.SZ): Currently, there is no relevant data on Assets.
Gelonghui reported on February 20 that Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform that the company currently has no relevant data assets.
Overview of the lifting of restrictions on trading A-shares | February 17.
According to the Zhitong Finance APP, on February 17, a total of 19 listed companies have unlocked their restricted shares, with a total market value of approximately 6.288 billion yuan. Today's specific situation of the unlocked restricted shares is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Share Number Luzhou Laojiao 000568 Stock-based Incentive 0.0371 million Jinling Pharmaceutical 000919 Stock-based Incentive 1.92 million Hubei Guangji Pharmaceutical 000952 Stock-based Incentive 2.5209 million JiangSu WuZhong Pharmaceutical Development 600200 Stock-based Incentive 0.9612 million China National Software & Service 600536 Stock-based Incentive 0.0572 million Shinva Medical Instrument 6005
Jinling Pharmaceutical: Jinling Pharmaceutical Co., Ltd. 2024 Annual Performance Forecast
Jinling Pharmaceutical (000919.SZ): The subsidiary involved in Retirement business currently mainly adopts the Institutions Retirement Operation model.
On January 8, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform that its subsidiary, which is involved in Retirement Business, mainly adopts an Institutional Retirement model for Operation. The Hefei Jinling Tianyi Smart Retirement project under construction plans to utilize a smart health retirement model to provide customers with intelligent elderly living, smart health management, intelligent Leisure experiences, and other retirement and rehabilitation services. It also plans to offer home-based retirement services in accordance with national policies and market-oriented Operation models.
Jinling Pharmaceutical (000919.SZ): Currently collaborating on technical Business with Nanjing University, China Pharmaceutical University, and other institutions.
On January 6th, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) indicated in their investor interaction platform that the company is currently collaborating with Nanjing University, China Pharmaceutical University, and other institutions on technology and business.
Jinling Pharmaceutical (000919.SZ): No related technology or research on Brain-computer Interface.
On December 26, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform that the company has no Brain-computer Interface related technology or research.
Market Is Not Liking Jinling Pharmaceutical's (SZSE:000919) Earnings Decline as Stock Retreats 11% This Week
Jinling Pharmaceutical (000919.SZ): Magnesium sulfate injection has been approved for registration.
On December 11, 2023, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) announced that its subsidiary, Nanjing Jinling Pharmaceutical Factory, received a "Pharmaceutical Registration Certificate" for magnesium sulfate injection issued by the National Medical Products Administration (Notification Number: 2024S30151). Magnesium sulfate injection can be used as an anticonvulsant for pregnancy-induced hypertension, to lower blood pressure, and to treat preeclampsia and eclampsia. Magnesium sulfate plays an important role in the prevention and treatment of eclampsia, hypertensive crises, asthma, and other diseases. Currently, China's "Guidelines for the Diagnosis and Treatment of Hypertensive Disorders in Pregnancy (2020)" ...
Jinling Pharmaceutical Completes Cancellation of Subsidiary
Jinling Pharmaceutical: Report for the third quarter of 2024
Jinling Pharmaceutical (000919.SZ): Intends to acquire a portion of shares of Xingong Fund and equity of non-cash distribution of Xingong Fund.
GeLongHui October 21st 丨 Jinling Pharmaceutical (000919.SZ) announced that, to build the company's global strategy of "medical and health care dual platform", improve the company's medical regional market layout, and at the same time resolve the same industry competition between Nanjing New Work Investment Group Co., Ltd. (referred to as "New Work Group") controlling Nanjing Meishan Hospital Co., Ltd. (referred to as "Nanjing Meishan Hospital") and the company, the company plans to acquire 164.7317 million yuan held by New Work Group South New Work Medical Industry Investment Fund Partnership Enterprise (Limited Partnership) (referred to as "Fund" or "New Work Fund") 28.46% of the contribution.
Unpleasant Surprises Could Be In Store For Jinling Pharmaceutical Company Limited's (SZSE:000919) Shares
The One-year Earnings Decline Is Not Helping Jinling Pharmaceutical's (SZSE:000919 Share Price, as Stock Falls Another 9.0% in Past Week
Jinling Pharmaceutical: 2024 Semi-Annual Report Summary
Jinling Pharmaceutical: Semi-Annual Report 2024
Jinling Pharmaceutical (000919.SZ) released its performance for the first half of the year, with a net income of 51.8188 million yuan, a decrease of 33.16%.
Jinling Pharmaceutical (000919.SZ) released its 2024 interim report. During the reporting period, the company achieved revenue...
Jinling Pharmaceutical (000919.SZ): The net income in the first half of the year was 51.8188 million yuan, a year-on-year decrease of 33.16%.
Jinling Pharmaceutical (000919.SZ) announced its semi-annual report for 2024, with revenue of 1.511 billion yuan, a year-on-year increase of 4.83%; net income attributable to shareholders of listed company was 51.8188 million yuan, a year-on-year decrease of 33.16%; net income attributable to shareholders of listed company after deducting non-recurring gains and losses was 45.2629 million yuan, a year-on-year decrease of 36.04%; basic earnings per share was 0.0913 yuan.
Jinling Pharmaceutical (000919.SZ): As of July 31st, the total number of shareholders in the company is 36,202.
Jinling Pharmaceutical (000919.SZ) stated on its investor interaction platform on August 1st that as of July 31st, 2024, the total number of shareholders in the company is 36,202.